Abstract:Abstract An immunomodulatory protein called the progesterone induced blocking factor (PIBF) is essential for the fetal semi-allograft to escape immune surveillance. Many cancer cell lines make both mPRs for PIBF and the protein itself. The progesterone receptor (PR) antagonist mifepristone added to cancer cell line cultures down-regulated mRNA for PIBF and the PIBF protein. This IRB approved study (that required a compassionate use IND from the FDA) evaluated oral mifepristone 200mg per day (majority) or 300mg in patients with very advanced cancers with no more treatment options available. Patients would remain under the care of their primary oncologists (FDA requirement). Because the nuclear (n) PR may be protective against cancer spread, only patients with cancers negative for the nPR were treated. Patients with the following types of cancers received mifepristone: non-small cell lung cancer (NSCLC) (n=9), small cell lung cancer (SCLC) (n=2), colon (n=3), pancreatic (n=2), thymic epithelial cell (n=1), transitional cell carcinoma of the renal pelvis (n=1), malignant fibrous histiocytoma (n=1), glioblastoma multiforme stage IV (n=1), leiomyosarcoma (n=1). All 21 patients showed significant palliative benefits, especially but not limited to, marked reduction in pain and marked improvement in energy, decreased dyspnea on exertion, and return of mental clarity. For those who had repeat CT evaluation no one failed to show shrinkage and decrease in malignant lesions and 2 (leiomyosarcoma and SCLC) showed complete remission after a few months on mifepristone. Five patients (3 females, 2 males) with SCLC (1), NSCL (n=3) and fibrous osteosarcoma (n=1) survived at least 5 years with 2 dying from cancer unrelated causes (SCLC and NSCLC). Two are still alive (NSCLC with EGFR mutation and brain metastases). The male with fibrous osteosarcoma died after stopping mifepristone in favor of a new drug recommended by his oncologist. Two patients lived over 2 years. Most would have lived longer had they not stopped mifepristone. Other observations: significant palliative benefits are seen within 3 weeks of taking mifepristone before any evidence of significant tumor regression. After a period of time, some lesions (especially in the primary location) may start growing slowly, but this is not a sign of loss of drug efficacy and long good quality life is still probable if one remains on the drug. The cancer spreads rapidly if one stops the mifepristone. The usual reason for stopping the drug was intervention by the primary oncologist suggesting a new clinical trial because there has not been complete remission of the cancer or some tumor growth (usually slow) or finances. Not one patient had a side effect. Hopefully this study will generate interest in treating patients with advanced cancer with mifepristone, especially those devoid of the nPR. These data support the role of mPRs in cancer proliferation. Citation Format: Jerome H. Check, Diane Check, Brooke Neumann, Carrie Wilson. Evidence that membrane progesterone receptors (mPR) play a key role in cancer metastases in most cases of metastatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3587.

Mifepristone inhibited tumor progression by disrupting the stability of PD-L1 by miR-127-3p/VAMP2 in ovarian cancer.

Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex

Effects of Mifepristone on Proliferation of Human Gastric Adenocarcinoma Cell Line SGC-7901 in Vitro

INHIBITORY EFFECTS OF MIFEPRISTONE ON THE GROWTH OF HUMAN GASTRIC CANCER CELL LINE MKN-45 IN VITRO AND IN VIVO

Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.

Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines

Effects of Mifepristone on the Growth and Metastasis of Human Gastric Cancer in Vivo and in Vitro

Reversal of Multidrug Resistance in Drug-Resistant Human Gastric Cancer Cell Line Sgc7901/Vcr by Antiprogestin Drug Mifepristone

Effect of Mifepristone on Migration and Proliferation of Oral Cancer Cells

Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression

Action of mifepristone on the expression of insulin-like growth factor binding protein-1 mRNA and protein during the early luteal phase in the human oviduct.

Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo.

MiR-5195-3p functions as a tumor suppressor by targeting RHBDD1 in ovarian cancer

MicroRNA-126 Affects Ovarian Cancer Cell Differentiation and Invasion by Modulating Expression of Vascular Endothelial Growth Factor

Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.

MicroRNA-664a-3p inhibits the proliferation of ovarian granulosa cells in polycystic ovary syndrome and promotes apoptosis by targeting BCL2A1

The Effect of Mifepristone on the Expression of Insulin-Like Growth Factor Binding Protein-1, Prolactin and Progesterone Receptor Mrna and Protein During the Implantation Phase in Human Endometrium

MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer

Mifepristone increases AQP1 mRNA expression, angiogenesis, and cell permeability through the ERK MAPK pathway

REVERSAL EFFECTS OF MIFEPRISTONE ON MULTIDRUG RESISTANCE（MDR） IN DRUG-RESISTANT BREAST CANCER CELL LINE MCF7/ADR IN VITRO AND IN VIVO

Abstract 3587: Evidence that membrane progesterone receptors (mPR) play a key role in cancer metastases in most cases of metastatic cancer